GuruFocus.com42d agoneutral
Novo Nordisk Stock Rises After GLP-1 Antitrust WinDismissal removes one legal challenge involving compounded alternatives while Novo confronts intensifying commercial competition in obesity treatments.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
71last 24h
974last 7d
109● bullish (7d)
123● bearish (7d)
212publishers
GuruFocus.com43d agoneutral
Lilly and Novo Win a Key GLP-1 Antitrust FightA Texas judge dismissed claims that the drugmakers illegally blocked access to compounded weight-loss drugs.